DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von ...

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a ...

Although not Federal Drug Administration-approved for treatment of UGI bleeding, intravenous pantoprazole is being used for this condition as a non-formulary indication. PPI therapy is an ...

The federal government will spend $20 million to expand the only local manufacturing facility of IV fluids. Production of the medicine is expected to jump from 60 million units a year to 80 ...

It is approved for administration as a single 5-second IV bolus. The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according to ...

TNKase is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration compared to the standard-of-care, Activase, which is administered as an IV bolus followed by ...

The drug is administered as a single, 5-second intravenous bolus — a faster and simpler administration compared to the standard of care 60-minute infusion of alteplase (Activase; Genentech), the ...

Genentech’s new stroke drug is delivered as a single five-second intravenous (IV) bolus, whereas Activase is administered as an IV bolus followed by a one-hour infusion. The differences in ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA ...